###begin article-title 0
Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity
###end article-title 0
###begin p 1
###xml 32 62 32 62 <email xmlns:xlink="http://www.w3.org/1999/xlink">zaghouanih@health.missouri.edu</email>
CORRESPONDENCE Habib Zaghouani: zaghouanih@health.missouri.edu
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 550 551 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 554 555 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 814 815 782 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 818 819 786 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
Primary neonatal T cell responses comprise both T helper (Th) cell subsets, but Th1 cells express high levels of interleukin 13 receptor alpha1 (IL-13Ralpha1), which heterodimerizes with IL-4Ralpha. During secondary antigen challenge, Th2-produced IL-4 triggers the apoptosis of Th1 cells via IL-4Ralpha/IL-13Ralpha1, thus explaining the Th2 bias in neonates. We show that neonates acquire the ability to overcome the Th2 bias and generate Th1 responses starting 6 d after birth. This transition was caused by the developmental maturation of CD8alpha+CD4- dendritic cells (DCs), which were minimal in number during the first few days of birth and produced low levels of IL-12. This lack of IL-12 sustained the expression of IL-13Ralpha1 on Th1 cells. By day 6 after birth, however, a significant number of CD8alpha+CD4- DCs accumulated in the spleen and produced IL-12, which triggered the down-regulation of IL-13Ralpha1 expression on Th1 cells, thus protecting them against IL-4-driven apoptosis.
###end p 3
###begin p 4
Abbreviations used: Ag, antigen; BFA, Brefeldin A; FcgammaR, Fc gamma receptor; Tg, transgenic.
###end p 4
###begin p 5
H.-H. Lee and C.M. Hoeman contributed equally to this paper.
###end p 5
###begin p 6
###xml 74 82 <span type="species:ncbi:9606">Children</span>
H.-H. Lee's present address is Division of Immunology, Karp Laboratories, Children's Hospital, Harvard Medical School, Boston, MA 02115.
###end p 6
###begin p 7
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 414 415 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
Secondary exposure to antigen (Ag) in neonates usually leads to a lack of Th1 cells and a bias toward Th2 immunity (1-4). This unbalanced response may explain the susceptibility of neonates to microbial infections and allergic reactions (5). Strategies aimed at balancing neonatal Th1 and Th2 responses may thus facilitate the development of effective vaccines against infections (6) and treatments for allergies (7). Recently, we and others have discovered that both Th1 and Th2 cells develop during the primary response to Ag in neonates (8, 9). However, a second encounter with Ag gives rise to a strong Th2 response and a weak Th1 response.
###end p 7
###begin p 8
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 728 729 728 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 832 833 824 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c</sub>
###xml 849 851 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 1097 1099 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1101 1103 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1331 1332 1299 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 504 507 <span type="species:ncbi:31658">CFA</span>
Using OVA-specific TCR transgenic (Tg) DO11.10 T cells (10), we developed a neonate-to-neonate transfer system that allows us to track the fate of primary Th1 cells upon exposure to Ag (11). In this system, neonatal splenic T cells from 1-d-old DO11.10/scid mice are transferred into newborn (1-d-old) BALB/c mice, which are then challenged with Ag i.p. 2 wk later, primary T cell responses are evaluated in the spleen. Secondary responses are examined in this model by rechallenging the mice with Ag in CFA at 7 wk of age and analyzing T cell responses 10 d later. Using this model, we have shown that the lack of secondary Th1 responses stems from the apoptosis of Th1 cells driven by IL-4 produced by their Th2 counterparts (9). In this system, IL-4 does not signal through the conventional type I IL-4 receptor (IL-4Ralpha/gammac) on Th1 cells (12). Rather, primary exposure to Ag induces the up-regulation of the IL-13Ralpha1 chain, which associates with IL-4Ralpha, giving rise to an IL-4Ralpha/IL-13Ralpha1 heteroreceptor, or type II receptor, through which both IL-4 and IL-13 can signal (13, 14). During in vitro recall or in vivo rechallenge with Ag, IL-4 from the Th2 cells utilizes the IL-4Ralpha/IL-13Ralpha1 heteroreceptor to drive apoptosis of Th1 cells, thus biasing the secondary immune response toward Th2 cells (9).
###end p 8
###begin p 9
###xml 367 368 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 371 372 355 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1464 1467 1412 1415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1508 1509 1452 1453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1512 1513 1456 1457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1671 1674 1607 1610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1683 1684 1615 1616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1687 1688 1619 1620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1045 1049 <span type="species:ncbi:10090">mice</span>
In this study, we investigated the mechanism underlying the up-regulation of IL-13Ralpha1 in neonatal Th1 cells. Our data indicate that the delayed developmental maturation of a subset of DCs leads to a shortage in IL-12 production, allowing for up-regulation of IL-13Ralpha1 expression and its association with the IL-4Ralpha chain. Indeed, we show that the CD8alpha+CD4- DCs accumulate to a significant level by day 6 after birth, a time point at which expression of IL-13Ralpha1 decreases, leading to diminished Th1 cell apoptosis and the restoration of IFN-gamma production by Th1 cells upon secondary Ag challenge. Neutralization of endogenous IL-12 on day 6 restored IL-13Ralpha1 expression and apoptosis of neonatal Th1 cells, thus inhibiting secondary IFN-gamma responses, and supplying exogenous IL-12 during exposure to Ag at birth decreased IL-13Ralpha1 expression and inhibited apoptosis of primary Th1 cells, allowing the generation of secondary Th1 responses. Consistent with this, the transfer of wild-type adult DCs into newborn mice that had previously received neonatal DO11.10 T cells inhibited the expression of IL-13Ralpha1, leading to the survival of primary Th1 cells and the production of IFN-gamma during secondary Ag challenge. In contrast, the transfer of IL-12-deficient DCs led to sustained IL-13Ralpha1 expression, Th1 cell apoptosis, and, thus, a lack of IFN-gamma production during the secondary response. Finally, transfer of IL-12+/+, but not IL-12-deficient, adult CD8alpha+CD4- DCs also inhibited IL-13Ralpha1 expression and Th1 cell apoptosis, and restored secondary IFN-gamma production by Th1 cells. The effect of transferring IL-12+/+ CD8alpha+CD4- DCs was reversed if IL-12 was neutralized at the time of Ag exposure.
###end p 9
###begin title 10
RESULTS
###end title 10
###begin title 11
Day 6 after birth represents a turning point for the expression of IL-13Ralpha1 and the development of neonatal Th1 immunity
###end title 11
###begin p 12
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 652 653 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 709 710 709 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 807 809 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 828 834 820 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 1000 1008 988 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 1340 1348 1320 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1579 1594 1555 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, C and D</xref>
###xml 167 172 <span type="species:ncbi:10090">mouse</span>
###xml 891 895 <span type="species:ncbi:10090">mice</span>
###xml 980 983 <span type="species:ncbi:31658">CFA</span>
###xml 1555 1558 <span type="species:ncbi:31658">CFA</span>
Previously, we developed a neonate-to-neonate TCR Tg T cell transfer system that was adapted to overcome the limitations associated with the small size of the newborn mouse and made tracking T cell fate possible (8). In this system, neonatal (1-d-old) DO11.10 TCR Tg CD4 T cells that are specific for OVA 323-339 peptide (designated OVA) (10) are transferred into BALB/c newborns (1 d old), the recipients are exposed to Ag, and the T cells are traced with the TCR-OVA-specific anticlonotypic antibody KJ1-26 (15) and analyzed for response to Ag. Also, as Ag we used Ig-OVA, an Ig chimera expressing OVA peptide within the heavy chain variable region (9, 11), for the purpose of avoiding the use of adjuvant (4) and for optimization of peptide presentation by uptake through Fc gamma receptors (FcgammaRs) (16). As indicated in Fig. 1, neonatal DO11.10 T cells transferred to 1-d-old BALB/c mice and exposed to Ig-OVA do not produce IFN-gamma upon rechallenge with OVA peptide in CFA at adult stage (Fig. 1 A). When the transfer used 8-wk-old adult instead of neonatal T cells, secondary IFN-gamma responses developed. The lack of a secondary IFN-gamma response is because of the fact that neonatal Th1 cells undergo apoptosis upon reencounter with OVA peptide, as indicated by the substantial Annexin V staining relative to adult T cells (Fig. 1 B). However, if neonatal exposure to Ig-OVA occurs around day 6 after birth, the cells acquire the ability to develop secondary IFN-gamma responses both in the spleen and lymph node upon rechallenge with OVA/CFA at the age of 7 wk (Fig. 1, C and D). Overall, neonates acquire the ability to develop Th1 secondary responses when the initial exposure to Ag occurs on or beyond day 6 after birth.
###end p 12
###begin p 13
###xml 0 137 0 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Neonates acquire the ability to develop secondary Th1 responses when the primary encounter with Ag occurs on or beyond day 6 after birth.</bold>
###xml 175 176 175 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 296 297 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 458 459 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 809 810 790 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 821 822 798 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 877 878 854 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 1138 1139 1113 1114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1176 1177 1151 1152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
###xml 1057 1061 <span type="species:ncbi:10090">mice</span>
###xml 1106 1109 <span type="species:ncbi:31658">CFA</span>
Neonates acquire the ability to develop secondary Th1 responses when the primary encounter with Ag occurs on or beyond day 6 after birth. Newborn BALB/c mice were given 3 x 104 neonatal or adult DO11.10 CD4 T cells and injected with 100 mug Ig-OVA in saline, and 2 wk later, the splenic cells (106 cells per well) were stimulated with 10 muM OVA peptide in vitro. (A) Production of IFN-gamma was measured by ELISA. (B) Apoptosis of IFN-gamma-producing KJ1-26+ Th1 cells was evaluated by Annexin V staining. In B, 10 mug/ml BFA was added after 6 h of stimulation with OVA peptide, and the culture was continued for another 6 h to facilitate intracellular accumulation of IFN-gamma. The cells were then labeled with KJ1-26 and Annexin V, and stained for intracellular IFN-gamma. Histogram shows gating on KJ1-26+/ IFN-gamma+ cells. (C and D) Newborn BALB/c mice were given 3 x 104 neonatal DO11.10 T cells within 24 h after birth and were injected with 60 mug/g Ig-OVA (to adjust for growth) on day 1, 2, 4, 6, 8, or 10 after T cell transfer. 2 mo later, the mice were challenged with 125 mug OVA peptide in CFA. 10 d later, the splenic (106 cells/well) and lymph node (0.5 x 106 cells/well) cells were stimulated with 10 muM OVA peptide for 24 h, and production of IFN-gamma was determined by ELISPOT. Each bar represents the mean +/- SD of triplicate wells. The data are representative of two experiments.
###end p 13
###begin p 14
###xml 222 223 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 271 273 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 275 277 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 528 529 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1087 1095 1047 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1491 1499 1439 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1768 1776 1704 1712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 1953 1961 1885 1893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
###xml 2014 2026 1946 1954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-13R&#945;1</italic>
###xml 2033 2035 1961 1963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 827 831 <span type="species:ncbi:10090">mice</span>
###xml 2145 2151 <span type="species:ncbi:9986">rabbit</span>
We have previously shown that exposure to Ig-OVA at the neonatal stage induces up-regulation of IL-13Ralpha1 on Th1 cells and that such a chain associates with IL-4Ralpha to form an IL-4Ralpha/IL-13Ralpha1 heteroreceptor (9) through which both IL-4 and IL-13 can signal (13, 14). Also, neonatal exposure to Ig-OVA induces both Th1 and Th2 cells in the primary response, and upon rechallenge with OVA peptide the Th2 cells produce IL-4 that uses the IL-4Ralpha/IL-13Ralpha1 heteroreceptor on Th1 cells to signal for their death (9). Because restoration of secondary IFN-gamma responses could occur when the primary exposure to Ig-OVA takes place around day 6 after birth, we sought to test whether at that point in time exposure to Ig-OVA no longer sustains up-regulation of IL-13Ralpha1 expression. Accordingly, 1-d-old BALB/c mice that had received neonatal DO11.10 T cells were given Ig-OVA on day 1, 2, 4, 6, or 10 after T cell transfer, and 2 wk later their splenic Th1 cells were isolated on the basis of IFN-gamma secretion and tested for IL-13Ralpha1 mRNA expression. As shown in Fig. 2 A, IL-13Ralpha1 mRNA was up-regulated when exposure to Ig-OVA took place on day 1, 2, or 4 after birth. However, a significant decrease occurred when the Ig-OVA was given on day 6 or 10 after birth. Densitometry analysis indicated that IL-13Ralpha1 mRNA went down from 260% of GADPH mRNA on day 2 to 10% on days 6 and 10, indicating an inability of the Th1 cells to up-regulate IL-13Ralpha1 mRNA (Fig. 2 B). The decrease in IL-13Ralpha1 mRNA on day 6 after birth translates into reduction of cell-surface IL-13Ralpha1 protein. Indeed, IL-13Ralpha1 protein expression went down by 50% (from 91 to 41%) when exposure to Ag was performed on day 6 instead of day 1 after birth (Fig. 2 C). Furthermore, Western blot analysis of Th1 T cell lysates indicated similar results, as Il-13Ralpha1 decreased by half upon Ag exposure on day 6 instead of day 1 after birth (Fig. 2 D). The control 1C5 CTLL-2 cells transfected with the IL-13Ralpha1 gene (17) expressed IL-13Ralpha1 protein, whereas the untransfected wild-type CTLL cells did not, indicating that the rabbit anti-IL-13Ralpha1 antiserum is specific for IL-13Ralpha1 protein. Overall, IL-13Ralpha1 mRNA and protein expression decreased significantly when exposure to Ag was made on day 6 after birth.
###end p 14
###begin p 15
###xml 0 98 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Recovery of neonatal IFN-&#947; response coincides with down-regulation of IL-13R&#945;1 expression.</bold>
###xml 136 137 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 159 160 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 301 302 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 453 465 443 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-13R&#945;1</italic>
###xml 493 498 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 704 716 690 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-13R&#945;1</italic>
###xml 720 725 702 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 914 915 894 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 928 929 908 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1059 1060 1038 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1846 1848 1792 1794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 2256 2264 2188 2196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 892 896 <span type="species:ncbi:10090">mice</span>
###xml 1166 1172 <span type="species:ncbi:9986">rabbit</span>
###xml 1659 1665 <span type="species:ncbi:9986">rabbit</span>
Recovery of neonatal IFN-gamma response coincides with down-regulation of IL-13Ralpha1 expression. Newborn BALB/c mice were given 3 x 105 purified neonatal CD4+ DO11.10 T cells and injected i.p. with 60 mug/g Ig-OVA in saline at day 1, 2, 4, 6, or 10 after birth, and 2 wk later, the splenic cells (107 cells/ml) were stimulated for 10 h with 10 muM OVA peptide. (A) Subsequently, Th1 cells were isolated, and RNA was extracted and used for analysis of IL-13Ralpha1 gene expression as well as GAPDH control by spot-blot technology, as described in Materials and methods. (B) The intensity of radioactive spots was analyzed on a Molecular Imager FX using Quantity One software and presented as a ratio of IL-13Ralpha1 to GAPDH after deduction of the background intensity obtained with pUC19 DNA negative control. The bars represent the mean +/- SD of two experiments. (C and D) Newborn BALB/c mice were given 3 x 104 neonatal CD4+ DO11.10 T cells and injected i.p. with 60 mug/g Ig-OVA in saline at day 1 or 6 after birth, and 2 wk later, the splenic cells (106 cells/ml) were stimulated for 10 h with 10 muM OVA peptide. In C, the cells were stained with KJ1-26 and rabbit anti-IL-13Ralpha1 antiserum (1:100 dilution), and Th1 cells were identified by staining for intracellular IFN-gamma with anti-IFN-gamma antibody. Expression of surface IL-13Ralpha1 was determined by flow cytometry on cells gated for KJ1-26 expression and intracellular IFN-gamma production. In D, Th1 cells were purified as in A, lysed using NP-40 detergent, and run on a 10% acrylamide gel. Transfer was made onto a nitrocellulose membrane, and IL-13Ralpha1 protein was detected using rabbit anti-IL-13Ralpha1 antibodies (1:1,000 dilution). For control purposes, we used lysates from CTLL-2 cells transfected with a plasmid coding for cell-surface IL-13Ralpha1 (reference 17) or wild-type untransfected CTLL-2 cells. Band intensity was analyzed using the Molecular Imager FX, and the relative expression of IL-13Ralpha1 represents a percent ratio with 1 d as 100%. Each bar represents the mean +/- SD of duplicate samples. (E) IL-13Ralpha1 mRNA expression measured by spot intensity from the experiments in A and B is illustrated together with the IFN-gamma production presented in Fig. 1 C to correlate IL-13Ralpha1 down-regulation together with an increase in secondary IFN-gamma production.
###end p 15
###begin p 16
###xml 260 268 244 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
When IL-13Ralpha1 mRNA expression from these Th1 cells during neonatal exposure to Ig-OVA was superimposed upon IFN-gamma production in the secondary response, an inverse correlation between IL-13Ralpha1 mRNA and the secondary IFN-gamma response was observed (Fig. 2 C). Indeed, when neonatal exposure to Ig-OVA was performed on day 6, the mice began to develop secondary IFN-gamma responses when challenged with OVA peptide 2 mo later. Such IFN-gamma responses were even higher when the neonatal exposure to Ig-OVA took place on day 10 after birth. Overall, day 6 represents a time point at which exposure to Ag no longer up-regulates IL-13Ralpha1, leading to the survival of IFN-gamma-producing cells and the development of neonatal Th1 immunity.
###end p 16
###begin title 17
Exogenous IL-12 given during exposure to Ag on the day of birth reduces up-regulation of IL-13Ralpha1 on primary neonatal Th1 cells and restores IFN-gamma secondary responses
###end title 17
###begin p 18
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 836 844 832 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 1152 1160 1140 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 1436 1444 1416 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 1465 1473 1445 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 1708 1723 1680 1695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, E and F</xref>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 768 771 <span type="species:ncbi:31658">CFA</span>
###xml 850 854 <span type="species:ncbi:10090">mice</span>
###xml 1076 1080 <span type="species:ncbi:10090">mice</span>
###xml 1295 1298 <span type="species:ncbi:31658">CFA</span>
###xml 1378 1382 <span type="species:ncbi:10090">mice</span>
###xml 1674 1678 <span type="species:ncbi:10090">mice</span>
Previously, it has been shown that neonates demonstrate a poor ability to produce IL-12 (18), which justifies the lack of neonatal Th1 immunity because IL-12 is a key differentiation factor for Th1 cells. However, the primary response does indeed raise Th1 cells (8, 9), suggesting that the lack of neonatal secondary Th1 immunity is not due solely to defective differentiation. Given that IL-12 was shown to restore neonatal secondary splenic Th1 responses (4, 11), we thought that it may accomplish this effect by interfering with the up-regulation of IL-13Ralpha1 expression. To test this premise, newborn BALB/c mice were given neonatal DO11.10 T cells and were administered Ig-OVA together with rIL-12. 7 wk later, the animals were challenged with OVA peptide in CFA and their splenic secondary responses were analyzed. As seen in Fig. 3 A, the mice given IL-12 developed IFN-gamma responses, whereas control animals not given IL-12 had no measurable IFN-gamma responses. In line with these results is the observation that the apoptosis of Th1 cells from IL-12-recipient mice was significantly reduced relative to control animals not given IL-12 (Fig. 3 B). When the animals were evaluated for IL-13Ralpha1 expression 2 wk after exposure to Ig-OVA/IL-12 but before any rechallenge with OVA/CFA, the primary Th1 cells had significantly reduced IL-13Ralpha1 mRNA relative to mice given Ig-OVA but no IL-12, as measured by spot blot (Fig. 3 C) and real-time PCR (Fig. 3 D). Again, when the cells were analyzed for IL-13Ralpha1 protein, the supply of exogenous IL-12 together with Ig-OVA reduced IL-13Ralpha1 protein expression from 84 to 41% when compared with cells from mice that did not receive IL-12. (Fig. 3, E and F). Overall, exogenous IL-12 was capable of down-regulating IL-13Ralpha1 on primary Th1 cells, which inhibited their apoptosis during rechallenge with OVA peptide and restored the secondary IFN-gamma responses.
###end p 18
###begin p 19
###xml 0 120 0 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Exogenous IL-12 inhibits developmental IL-13R&#945;1 up-regulation and restores secondary Th1 IFN-&#947; response in vivo.</bold>
###xml 158 159 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 481 482 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 669 670 654 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 680 681 661 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 990 1002 968 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-13R&#945;1</italic>
###xml 1323 1324 1291 1292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 1437 1438 1405 1406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 1451 1452 1419 1420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1569 1570 1537 1538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 425 428 <span type="species:ncbi:31658">CFA</span>
###xml 865 869 <span type="species:ncbi:10090">Mice</span>
###xml 1356 1360 <span type="species:ncbi:10090">mice</span>
###xml 1420 1424 <span type="species:ncbi:10090">mice</span>
###xml 1675 1681 <span type="species:ncbi:9986">rabbit</span>
Exogenous IL-12 inhibits developmental IL-13Ralpha1 up-regulation and restores secondary Th1 IFN-gamma response in vivo. Newborn BALB/c mice were given 3 x 104 neonatal DO11.10 T cells within 24 h after birth. 1 d later, the recipient mice were given 100 mug Ig-OVA and 50 ng rIL-12. The mice were given additional IL-12 on days 2 and 3 after T cell transfer. 7 wk later, the mice were challenged with 125 mug OVA peptide in CFA, and 10 d after the challenge, the splenic cells (106 cells/well) were stimulated for 24 h with 10 muM OVA peptide. (A and B) Subsequently, IFN-gamma was measured by ELISPOT (A) and apoptosis was evaluated using Annexin V staining of KJ1-26+/IFN-gamma+ splenic cells (B). For Annexin V staining, 10 mug/ml BFA was added during the last 8 h of peptide stimulation. Each bar in A represents the mean +/- SD of triplicate wells. (C and D) Mice that received neonatal DO11.10 T cells were given Ig-OVA and IL-12 as in A, and 2 wk later, Th1 cells were isolated and IL-13Ralpha1 expression was assessed by spot blot (C) and real-time PCR (D). The real-time PCR used 200 ng RNA and the Absolute QRT-PCR SYBR kit to determine IL-13Ralpha1 mRNA. For the spot blot in C, each bar represents the mean +/- SD of duplicate spots. For the real-time PCR, the bars represent the comparative threshold cycle (CT). The value of the sample from mice not receiving IL-12 was set as 1. (E and F) Newborn BALB/c mice given 3 x 104 neonatal CD4+ DO11.10 T cells were exposed to Ig-OVA in the presence of IL-12 as in A and B, and 2 wk later, the splenic cells (106 cells/ml) were stimulated for 10 h with 10 muM OVA peptide. The cells were then stained with KJ1-26 and rabbit anti-IL-13Ralpha1 antiserum (1:100 dilution), and Th1 cells were identified by staining for intracellular IFN-gamma with anti-IFN-gamma antibody. Expression of surface IL-13Ralpha1 was determined by flow cytometry on cells gated for KJ1-26 expression and intracellular IFN-gamma production.
###end p 19
###begin title 20
Day 6 transition to Th1 responses is caused by an acquired ability of the neonate to produce IL-12 that down-regulates IL-13Ralpha1 and sustains the survival of IFN-gamma-producing T cells
###end title 20
###begin p 21
###xml 503 511 491 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 874 882 854 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1251 1266 1227 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, C and D</xref>
###xml 1365 1380 1337 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, E and F</xref>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 425 428 <span type="species:ncbi:31658">CFA</span>
###xml 693 696 <span type="species:ncbi:10116">rat</span>
###xml 710 714 <span type="species:ncbi:10090">mice</span>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
###xml 865 868 <span type="species:ncbi:10116">rat</span>
###xml 1176 1180 <span type="species:ncbi:10090">mice</span>
###xml 1234 1237 <span type="species:ncbi:10116">rat</span>
###xml 1549 1553 <span type="species:ncbi:10090">mice</span>
###xml 1580 1583 <span type="species:ncbi:10116">rat</span>
###xml 1667 1671 <span type="species:ncbi:10090">mice</span>
Because exogenous IL-12 was able to reduce IL-13Ralpha1 expression and rescue neonatal primary Th1 cells similar to Ag exposure on day 6, we postulated that the newborn acquires the ability to produce significant IL-12 on day 6, which results in IL-13Ralpha1 down-regulation and rescue of Th1 immunity. To test this premise, mice were given Ig-OVA and anti-IL-12 antibody on day 6 after birth, challenged with OVA peptide in CFA 2 mo later, and tested for IFN-gamma production as well as Th1 apoptosis. Fig. 4 A shows that neutralization of IL-12 during exposure to Ig-OVA on day 6 reduces IFN-gamma production to minimal levels comparable to those observed with day 1 exposure to Ag, whereas rat IgG-injected mice sustain significant IFN-gamma responses. Also, apoptosis of Th1 cells was more substantial in the mice given anti-IL-12 antibody versus recipients of rat IgG (Fig. 4 B). These results indicate that the restoration of secondary Th1 responses upon delay of Ag exposure to day 6 after birth operates through the production of endogenous IL-12. Interestingly, IL-13Ralpha1 mRNA expression analyzed 2 wk after day 6 Ag exposure was significantly up-regulated in the mice given anti-IL-12 antibody versus those recipients of rat IgG instead (Fig. 4, C and D). Similar results were observed when the cells were analyzed for IL-13Ralpha1 protein expression (Fig. 4, E and F). Indeed, neutralization of IL-12 with ant-IL-12 antibody during day 6 exposure to Ig-OVA reduced IL-13Ralpha1 protein expression from 72 to 43% relative to cells from mice that received the control rat IgG instead of anti-IL-12 antibody. Overall, the findings suggest that the newborn mice acquire the ability to produce significant IL-12 by day 6 after birth that is sufficient for down-regulation of IL-13Ralpha1, survival of Th1 cells, and restoration of secondary IFN-gamma responses.
###end p 21
###begin p 22
###xml 0 139 0 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Neutralization of IL-12 on day 6 after birth nullifies IFN-&#947; response through up-regulation of IL-13R&#945;1 and apoptosis of Th1 cells.</bold>
###xml 177 178 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 629 630 618 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 782 788 766 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1097 1103 1075 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1261 1262 1237 1238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 315 320 <span type="species:ncbi:10090">mouse</span>
###xml 324 327 <span type="species:ncbi:10116">rat</span>
###xml 377 380 <span type="species:ncbi:10116">rat</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
###xml 591 594 <span type="species:ncbi:31658">CFA</span>
###xml 857 861 <span type="species:ncbi:10090">Mice</span>
###xml 1294 1298 <span type="species:ncbi:10090">mice</span>
###xml 1313 1316 <span type="species:ncbi:10116">rat</span>
###xml 1410 1413 <span type="species:ncbi:10116">rat</span>
###xml 1536 1542 <span type="species:ncbi:9986">rabbit</span>
Neutralization of IL-12 on day 6 after birth nullifies IFN-gamma response through up-regulation of IL-13Ralpha1 and apoptosis of Th1 cells. Newborn BALB/c mice were given 3 x 104 CD4 neonatal DO11.10 T cells within 24 h after birth. On day 6, the hosts were given 60 mug/g Ig-OVA and 50 mug anti-IL-12 antibody per mouse or rat IgG. Another injection of anti-IL-12 antibody or rat IgG was given on days 7 and 8. A group of mice that received Ig-OVA on day 1 and no anti-IL-12 antibody at any time was included as a control. 7 wk later, all groups were challenged with 125 mug OVA peptide in CFA. 10 d later, the splenic cells (106 cells/well) were stimulated with 10 muM OVA peptide and assayed for (A) IFN-gamma production by ELISPOT and (B) apoptosis by Annexin V staining, as in Fig. 3. Each bar represents the mean +/- SD of triplicate wells. (C and D) Mice that received neonatal DO11.10 T cells were given Ig-OVA and anti-IL-12 antibody as in A, and 2 wk later, primary Th1 cells were isolated and IL-13Ralpha1 expression was assessed by spot blot (C) and real-time PCR (D), as described in Fig. 3. For the spot blot in C, each bar represents the mean +/- SD of duplicate spots. For the real-time PCR, the bars represent the comparative threshold cycle (CT). The value of the sample from mice that received rat IgG was set as 1. (E and F) Newborn BALB/c from A and B that received anti-IL-12 antibody or rat IgG control during exposure to Ig-OVA on day 6 were killed 2 wk later, and the splenic cells were stained with KJ1-26 and rabbit anti-IL-13Ralpha1 antiserum (1:100 dilution). The Th1 cells were identified by staining for intracellular IFN-gamma with anti-IFN-gamma antibody, and expression of surface IL-13Ralpha1 was determined by flow cytometry on cells gated for KJ1-26 expression and intracellular IFN-gamma production.
###end p 22
###begin title 23
Enrichment with adult DCs inhibits IL-13Ralpha1 up-regulation on primary neonatal Th1 cells and restores secondary IFN-gamma responses
###end title 23
###begin p 24
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 584 590 580 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 769 772 765 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 785 788 781 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 794 809 790 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A and B</xref>
###xml 855 858 851 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 861 863 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 881 884 877 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1044 1052 1040 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 1058 1066 1054 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 1105 1108 1101 1104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1230 1233 1222 1225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1283 1291 1275 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 1391 1394 1383 1386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1497 1500 1485 1488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1538 1546 1522 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 E</xref>
###xml 1628 1631 1612 1615 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
###xml 774 778 <span type="species:ncbi:10090">mice</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
###xml 1010 1014 <span type="species:ncbi:10090">mice</span>
###xml 1121 1125 <span type="species:ncbi:10090">mice</span>
###xml 1193 1197 <span type="species:ncbi:10090">mice</span>
###xml 1316 1320 <span type="species:ncbi:10090">mice</span>
###xml 1346 1349 <span type="species:ncbi:31658">CFA</span>
IL-12 is produced by APCs, most significantly by DCs, during Ag presentation and direct T cell differentiation to Th1 (19). Most of the APCs in the neonate, however, are composed of macrophages and B cells, with a minimal number of DCs (11). It is thus possible that the lack of IL-12 in the neonates is caused by delayed developmental accumulation of DCs. To test this assumption, we enriched the neonates with splenic DCs from adult mice and tested them for rescue of primary neonatal Th1 cells from apoptosis and development of secondary Th1 IFN-gamma responses. As can be seen in Fig. 5, binding of Annexin V to neonatal Th1 DO11.10 T cells decreased from 87% in the mice that did not receive DCs (Nil) to 12% in those that received DCs from IL-12-sufficient (IL-12+/+) mice (IL-12+/+ DCs; Fig. 5, A and B). Transfer of DCs from IL-12-deficient (IL-12-/-) (20) instead of IL-12+/+ mice did not reduce Th1 cell death, as binding of Annexin V was observed on 86% of the Th1 cells in comparison to 87% in the mice with no DC transfer (compare Fig. 5 C with Fig. 5 A). The primary Th1 cells from the IL-12+/+ DC-enriched mice had reduced expression of IL-13Ralpha1 mRNA relative to T cells of mice that were transferred with IL-12-/- DCs or animals that did not receive DC transfer (Fig. 5 D). Furthermore, when the mice were challenged with OVA/CFA at 7 wk of age, those recipients of IL-12+/+ DCs developed secondary IFN-gamma responses, whereas animals that were not given DCs or received IL-12-/- DCs had minimal IFN-gamma responses (Fig. 5 E). The conclusion to be drawn from these experiments is that enrichment with IL-12+/+ DCs is similar to treatment with exogenous IL-12, which reduces IL-13Ralpha1 expression by Th1 cells, leading to the inhibition of apoptosis and restoration of secondary IFN-gamma responses.
###end p 24
###begin p 25
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 40 43 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 0 173 0 165 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Transfer of adult IL-12<sup>+/+</sup> but not IL-12<sup>&#8722;/&#8722;</sup> DCs into newborn mice down-regulates IL-13R&#945;1 expression, inhibits apoptosis, and restores secondary Th1 IFN-&#947; responses.</bold>
###xml 221 222 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 276 277 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 317 320 309 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 351 354 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 383 385 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 543 544 533 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 632 633 621 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 643 644 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 713 719 698 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 998 1004 975 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1071 1078 1044 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Figs. 2</xref>
###xml 1080 1081 1053 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">3</xref>
###xml 1087 1088 1060 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">4</xref>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 367 371 <span type="species:ncbi:10090">mice</span>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
###xml 501 504 <span type="species:ncbi:31658">CFA</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
Transfer of adult IL-12+/+ but not IL-12-/- DCs into newborn mice down-regulates IL-13Ralpha1 expression, inhibits apoptosis, and restores secondary Th1 IFN-gamma responses. Newborn (1-d-old) BALB/c mice were given 3 x 104 neonatal DO11.10 T cells without (Nil) or with 2 x 105 splenic DCs from adult wild-type (IL-12+/+ DCs) or IL-12-deficient (IL-12-/- DCs) BALB/c mice (reference 20) and were injected 1 d later with 100 mug Ig-OVA. After 7 wk, the mice were challenged with 125 mug OVA peptide in CFA, and 10 d later, the splenic cells (106 cells/well) were stimulated with 10 muM OVA peptide for 24 h. (A-C) Apoptosis of KJ1-26+/IFN-gamma+ Th1 cells was evaluated by staining with Annexin V, as described in Fig. 3. (D) Groups of mice were killed 2 wk after T cell/DC transfer and exposure to Ig-OVA, and primary Th1 cells were isolated using IFN-gamma secretion kit, as described in Materials and methods. RNA was then extracted and IL-13Ralpha1 expression was determined by spot blot, as in Fig. 2. Because IL-13Ralpha1 mRNA parallels with protein expression (see Figs. 2, 3, and 4), all follow-up experiments will use mRNA analysis on separated Th1 cells. (E) IFN-gamma production was measured using ELISPOT assay. Each bar represents the mean +/- SD of duplicate spots.
###end p 25
###begin title 26
###xml 50 51 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 54 55 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
Delayed developmental accumulation of the CD8alpha+CD4- subset of DCs in the neonates leads to minimal IL-12 production, significant up-regulation of IL-13Ralpha1 expression, death of primary Th1 cells, and lack of secondary IFN-gamma responses
###end title 26
###begin p 27
###xml 429 430 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 457 458 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 471 472 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 478 480 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 509 510 481 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 577 578 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 581 582 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 595 596 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 599 600 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 769 775 733 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 795 796 759 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 877 878 833 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 881 882 837 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 922 923 878 879 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 945 946 897 898 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 949 950 901 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 982 983 934 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1123 1124 1071 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1127 1128 1075 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1166 1167 1110 1111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1170 1171 1114 1115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1177 1183 1121 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 1268 1269 1208 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1272 1273 1212 1213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1294 1295 1230 1231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1298 1299 1234 1235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1393 1394 1325 1326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1397 1398 1329 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1460 1461 1392 1393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1602 1603 1530 1531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1606 1607 1534 1535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1620 1621 1544 1545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1624 1625 1548 1549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1966 1967 1878 1879 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1970 1971 1882 1883 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1983 1984 1891 1892 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1987 1988 1895 1896 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2022 2025 1930 1933 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 2034 2037 1942 1945 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2198 2206 2102 2110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 2328 2331 2228 2231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 2340 2341 2236 2237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2344 2345 2240 2241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2457 2460 2349 2352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 2469 2470 2357 2358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2473 2474 2361 2362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2480 2488 2368 2376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 2508 2511 2396 2399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2520 2521 2404 2405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2524 2525 2408 2409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2588 2596 2468 2476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 2684 2687 2564 2567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 2696 2697 2572 2573 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2700 2701 2576 2577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2723 2726 2599 2602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 2735 2736 2607 2608 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2739 2740 2611 2612 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2760 2771 2632 2643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, C&#8211;E</xref>
###xml 2867 2870 2739 2742 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 2879 2880 2747 2748 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2883 2884 2751 2752 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2904 2919 2772 2787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, C and D</xref>
###xml 3005 3008 2873 2876 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 3017 3018 2881 2882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3021 3022 2885 2886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 3028 3036 2892 2900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 E</xref>
###xml 3072 3073 2936 2937 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3076 3077 2940 2941 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 3168 3171 3032 3035 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 3175 3176 3039 3040 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3179 3180 3043 3044 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 3238 3246 3102 3110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 F</xref>
###xml 3304 3307 3168 3171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 3311 3312 3175 3176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3315 3316 3179 3180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 3387 3395 3251 3259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 H</xref>
###xml 3461 3464 3321 3324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 3473 3474 3329 3330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3477 3478 3333 3334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 3506 3509 3362 3365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 3518 3519 3370 3371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3522 3523 3374 3375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 3541 3544 3393 3396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 3553 3554 3401 3402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 3557 3558 3405 3406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3572 3580 3420 3428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 3623 3626 3471 3474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 3635 3636 3479 3480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3639 3640 3483 3484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 3734 3737 3574 3577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 3746 3747 3582 3583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3750 3751 3586 3587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 3841 3849 3677 3685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 3888 3889 3720 3721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3892 3893 3724 3725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1244 1248 <span type="species:ncbi:10090">mice</span>
###xml 1898 1902 <span type="species:ncbi:10090">mice</span>
###xml 2038 2042 <span type="species:ncbi:10090">mice</span>
###xml 2277 2281 <span type="species:ncbi:10090">mice</span>
Because DCs were able to reduce IL-13Ralpha1 expression, inhibit apoptosis of primary Th1 cells, and restore secondary IFN-gamma responses, we sought to determine whether delayed developmental accumulation of a specific subset of DCs is responsible for the up-regulation of IL-13Ralpha1 by virtue of minimal IL-12 production leading to the death of primary Th1 cells and a lack of secondary IFN-gamma responses. The splenic CD11c+ DCs comprise both CD8alpha+ and CD8alpha- DCs (21). Also, some of the CD8alpha- DCs can express CD4, and as such are further divided into CD8alpha-CD4+ and CD8alpha-CD4- DCs. Initially, we determined the kinetics of accumulation of various subsets of DCs in the splenic neonate between the day of birth and day 10 of age. As indicated in Fig. 6, most splenic CD11c+ DCs were negative for CD8alpha and CD4. However, by day 4 the number of CD8alpha-CD4+ DCs rose to 11.2% among the total CD11c+ DCs, whereas CD8alpha+CD4- DCs made up 3.3% of total CD11c+ cells. By day 6, both subsets reached a number that was more or less similar to days 8 and 10, which ranged between 13 and 16% for CD8alpha-CD4+ and between 3.8 and 4.3% for CD8alpha+CD4- DCs (Fig. 6). These numbers are much lower than those observed in adult mice (40.4% for CD8alpha-CD4+ and 16% for CD8alpha+CD4- DCs), indicating that developmental accumulation is not complete by day 10. In fact, CD8alpha+CD4+ DCs, which make up a very small fraction of total adult CD11c+ DCs, remain insignificant at day 10 of age. Because day 6 was a turning point for the development of Th1 secondary immunity and the CD8alpha-CD4+ and CD8alpha+CD4- DC subsets have undergone a significant increase in number between birth and day 6, we tested both populations for reduction of IL-13Ralpha1 up-regulation, inhibition of apoptosis of Th1 cells, and restoration of secondary IFN-gamma responses. Accordingly, newborn BALB/c mice were transferred with 1-d-old DO11.10 T cells with the CD8alpha-CD4+ or CD8alpha+CD4- adult DC subset from either IL-12+/+ or IL-12-/- mice and were exposed to Ig-OVA. 2 wk later, Th1 cells were isolated and IL-13Ralpha1 mRNA expression on primary neonatal Th1 cells was evaluated by spot blot. Fig. 7 A shows that up-regulation of IL-13Ralpha1 expression occurred when the mice received no DC transfer or transfer with IL-12+/+ CD8alpha-CD4+ DCs. However, up-regulation of IL-13Ralpha1 expression was minimal when the animals were transferred with IL-12+/+ CD8alpha+CD4- DCs (Fig. 7 A). Transfer of IL-12-/- CD8alpha+CD4- DCs did not reduce IL-13Ralpha1 mRNA expression on Th1 cells (Fig. 7 A). Moreover, apoptosis of Th1 cells was reduced significantly with the transfer of IL-12+/+ CD8alpha+CD4- DCs relative to IL-12+/+ CD8alpha-CD4+ or no DC transfer (Fig. 7, C-E). Indeed, 83 and 87% of primary Th1 cells bind Annexin V when the transfer used no DCs or IL-12+/+ CD8alpha-CD4+ DCs, respectively (Fig. 7, C and D). Only 45% of primary Th1 cells bound Annexin V when the transfer was made with IL-12+/+ CD8alpha+CD4- DCs (Fig. 7 E). Inhibition of T cell death by CD8+CD4- DC transfer is dependent on IL-12. This statement emanates from the observation that IL-12-/- CD8+CD4- DC transfer does not inhibit the apoptosis of Th1 cells (Fig. 7 F), but a supply of exogenous IL-12 together with the IL-12-/- CD8+CD4- DC transfer restores the reduction of Annexin V binding to Th1 cells (Fig. 7 H). Finally, secondary IFN-gamma responses did occur with the IL-12+/+ CD8alpha+CD4- DCs, but not with the IL-12-/- CD8alpha+CD4- or even the IL-12+/+ CD8alpha-CD4+ DC transfer (Fig. 7 B). Supply of exogenous IL-12 with the IL-12-/- CD8alpha+CD4- DCs restored IFN-gamma secondary responses. Furthermore, neutralization of IL-12 during IL-12+/+ CD8alpha+CD4- DC transfer by injection of anti-IL-12 antibody restored apoptosis of primary Th1 cells (Fig. 7 B). These results indicate that CD8alpha+CD4- DCs provide sufficient IL-12 needed for down-regulation of IL-13Ralpha1, inhibition of apoptosis, and restoration of secondary Th1 responses.
###end p 27
###begin p 28
###xml 38 39 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 42 43 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 56 57 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 60 61 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 94 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Developmental accumulation of CD8&#945;<sup>+</sup>CD4<sup>&#8722;</sup> and CD8&#945;<sup>&#8722;</sup>CD4<sup>+</sup> DCs occurs at day 6 after birth.</bold>
###xml 112 113 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
Developmental accumulation of CD8alpha+CD4- and CD8alpha-CD4+ DCs occurs at day 6 after birth. Splenic cells (106 cells/ tube) from 1-, 2-, 4-, 6-, 8-, and 10-d-old BALB/c neonates were stained with anti-CD11c, anti-CD4, and anti-CD8alpha antibodies, fixed with 2% formaldehyde, and analyzed by FACS. Expression of CD4 and CD8alpha was analyzed on cells gated on CD11c. Splenic cells from adult (8-wk-old) BALB/c mice were included as control. Percentages of cells are shown.
###end p 28
###begin p 29
###xml 12 13 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 16 17 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 38 39 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 42 43 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 156 0 140 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The CD8&#945;<sup>+</sup>CD4<sup>&#8722;</sup> but not the CD8&#945;<sup>&#8722;</sup>CD4<sup>+</sup> DC subset inhibits up-regulation of IL-13R&#945;1, prevents apoptosis, and restores neonatal IFN-&#947; responses.</bold>
###xml 237 238 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 247 248 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 251 252 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 264 265 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 268 269 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 290 293 266 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 302 305 278 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 714 715 678 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 893 894 852 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 904 905 859 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 988 991 943 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1000 1001 951 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1004 1005 955 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1238 1241 1188 1191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1249 1250 1195 1196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1253 1254 1199 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 676 679 <span type="species:ncbi:31658">CFA</span>
###xml 1023 1027 <span type="species:ncbi:10090">mice</span>
The CD8alpha+CD4- but not the CD8alpha-CD4+ DC subset inhibits up-regulation of IL-13Ralpha1, prevents apoptosis, and restores neonatal IFN-gamma responses. Newborn BALB/c mice were given neonatal DO11.10 T cells without (Nil) or with 105 CD8alpha+CD4- or CD8alpha-CD4+ DCs from adult IL-12+/+ or IL-12-/- BALB/c mice and were injected 24 h later with 100 mug Ig-OVA. (A) The mice were killed within 2 wk, primary Th1 cells were isolated on the basis of IFN-gamma secretion, and IL-13Ralpha1 expression was evaluated by spot blot. Each bar represents the mean +/- SD of duplicate spots. (B-H) 7 wk after exposure to Ig-OVA the mice were challenged with 125 mug OVA peptide in CFA. 10 d later, the splenic cells (106 cells/well) were stimulated for 24 h with 10 muM OVA peptide, and production of IFN-gamma was measured by ELISPOT (B) and apoptosis was evaluated by Annexin V staining of KJ1-26+/IFN-gamma+ splenic cells (C-H). For neutralization of endogenous IL-12 where indicated (IL-12+/+ CD8alpha+CD4-/anti-IL-12), the mice were given i.p. 50 mug anti-IL-12 antibody (clone C17.8) on days 1, 2, and 3 after neonatal transfer of DO11.10 T cells and DCs. For stimulation with OVA peptide in the presence of rIL-12 where indicated (IL-12-/-CD8alpha+CD4- + IL-12), the culture was supplemented with 2 ng/ml rIL-12. Each bar in B represents the mean +/- SD of triplicate wells.
###end p 29
###begin p 30
###xml 120 121 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 124 125 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 207 208 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 362 368 358 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 475 483 471 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 573 574 565 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 577 578 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 766 767 758 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 852 860 844 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
###xml 929 930 917 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 933 934 921 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 959 960 943 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 963 964 947 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 971 972 955 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 975 976 959 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1021 1022 1001 1002 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1025 1026 1005 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1034 1035 1014 1015 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1038 1039 1018 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1098 1104 1078 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 1162 1163 1138 1139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1166 1167 1142 1143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1305 1313 1281 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 C</xref>
###xml 1416 1417 1388 1389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1420 1421 1392 1393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1444 1445 1412 1413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1448 1449 1416 1417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1585 1600 1553 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8, D and E</xref>
To determine whether the limited availability of IL-12 on the day of birth is caused by delayed accumulation of CD8alpha+CD4- DCs or by an inability of these APCs to produce IL-12, we isolated neonatal CD11c+ DCs at different time points after birth, stimulated the cells with the DC stimulator CpG dinucleotide, and tested for IL-12 production. As indicated in Fig. 8, neonatal DCs gain the ability to produce IL-12 progressively over time and reach a maximum at adult age (Fig. 8 A). However, these results do not distinguish between an increase in the number of CD8alpha+CD4- DCs or the gain of ability to produce IL-12 cytokine. Given that isolation of the DC subsets at early neonatal age is not feasible because of low frequency, we opted to purify total CD11c+ DCs, stimulate them with CpG, and test for intracellular IL-12 on gated DC subsets. Fig. 8 B shows that on day 1 after birth most of the splenic DCs are CD8alpha-CD4-, with almost no CD8alpha+CD4- or CD8-CD4+ DC subsets. By day 6, however, both CD8alpha+CD4- and CD8-CD4+ DC subsets reached significant frequency, as was shown in Fig. 6. When tested for intracellular IL-12, 26% of the CD8alpha-CD4- double-negative and most frequent subset produced IL-12 on day 1 after birth, and 6 d later 84% of the cells displayed IL-12 expression (Fig. 8 C). This points to a developmental influence on these DCs to produce IL-12 cytokine. As for the CD8alpha+CD4- DCs, like the CD8alpha-CD4+ DCs, there was no detectable IL-12 on day 1 but the majority of the cells available on day 6 produced IL-12 (84 and 97%, respectively; Fig. 8, D and E). These results indicate that the limited availability of IL-12 on the day of birth is caused by delayed accumulation of the DC subsets in the spleen, together with a progressive ability to produce IL-12 cytokine.
###end p 30
###begin p 31
###xml 140 141 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 144 145 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 0 156 0 152 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The limited availability of IL-12 during neonatal exposure to Ag is related to delayed accumulation in the spleen of the presenting CD8&#945;<sup>+</sup>CD4<sup>&#8722;</sup> DC subset.</bold>
###xml 240 241 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 307 308 303 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 496 497 489 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 567 568 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 574 575 567 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
The limited availability of IL-12 during neonatal exposure to Ag is related to delayed accumulation in the spleen of the presenting CD8alpha+CD4- DC subset. Newborn BALB/c mice were killed at the indicated day after birth, and splenic CD11c+ DCs were isolated on anti-CD11c microbeads. (A) The DCs (100 x 103 cells per well) were stimulated with 6 mug/ml CpG, and 24 h later, IL-12 was measured by ELISA. Each bar represents the mean +/- SD of triplicate wells. (B-E) 1- and 6-d-old DCs (100 x 103 cells per well) were purified from the spleens of 45 newborns, and 106 CD11c+ cells were stimulated with 6 mug/ml CpG for 10 h, after which BFA was added and the culture was continued for 4 h to facilitate intracellular cytokine accumulation. Subsequently, the cells were stained with anti-CD11c, anti-CD4, and anti-CD8 antibodies and permeabilized with 2% saponin. Intracellular IL-12 was detected by staining with anti-IL-12 p70 antibody. B shows the frequency of the subsets, and C-E illustrates flow cytometry plots of intracellular IL-12 on the indicated subset. ND, not detected.
###end p 31
###begin title 32
DISCUSSION
###end title 32
###begin p 33
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 452 453 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 638 640 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 642 644 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 787 788 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 994 1000 962 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 1147 1149 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 1360 1366 1320 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1611 1612 1567 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 1614 1616 1570 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1694 1696 1650 1652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1698 1700 1654 1656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 2098 2104 2042 2048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 2373 2379 2309 2315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
Neonatal exposure to Ag leads to secondary responses that are usually biased toward Th2 upon rechallenge with Ag later (1-4). Recent investigations indicated that both Th1 and Th2 cells develop in the neonatal primary response, but secondary encounter with Ag leads to death of the Th1 cells by apoptosis, hence the bias toward Th2 cells (9). The death of Th1 cells stems from an up-regulation of the IL-13Ralpha1 chain during neonatal exposure to Ag (9). Indeed, it was shown that the IL-13Ralpha1 chain associates with IL-4Ralpha to form an IL-4Ralpha/IL-13Ralpha1 heteroreceptor through which both IL-4 and IL-13 cytokines can signal (13, 14). During rechallenge with Ag, IL-4 from the Th2 cells utilizes the IL-4Ralpha/IL-13Ralpha1 heteroreceptor and induces the death of Th1 cells (9). In this paper, we show that day 6 after birth is a turning point at which exposure to Ag no longer results in secondary responses that are biased toward Th2 and secondary Th1 IFN-gamma responses emerge (Fig. 1). These observations bode well with findings indicating that exposure to Ag at day 7 but not at day 3 become effective in inducing Th1 responses (22). Interestingly, day 6 after birth also represents a turning point for the expression of IL-13Ralpha1, as exposure to Ag at this age no longer up-regulates IL-13Ralpha1 mRNA or protein expression on Th1 cells (Fig. 2). We then set up experiments and investigated the mechanism underlying the restoration of neonatal Th1 secondary responses by day 6 Ag exposure. We have previously shown that IL-12 can rescue splenic Th1 cells and restore IFN-gamma production (4, 11). Given that the neonate displays an inability to produce significant IL-12 (19, 23), we thought that exposure to Ag within an environment where IL-12 is limited may be responsible for up-regulation of IL-13Ralpha1 and the consequent death of Th1 cells. This assumption proved correct, as exogenous IL-12 given during Ag exposure on day 1 reduced IL-13Ralpha1 mRNA and protein expression on primary Th1 cells, inhibited their apoptosis, and restored secondary IFN-gamma responses (Fig. 3). Moreover, it was shown that the administration of anti-IL-12 antibody during Ag exposure on day 6 after birth nullifies restoration of secondary IFN-gamma responses, and this operates through the restitution of IL-13Ralpha1 up-regulation and apoptosis of Th1 cells (Fig. 4).
###end p 33
###begin p 34
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 380 383 380 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 551 557 543 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 565 568 557 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 937 939 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 940 942 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 1012 1015 992 995 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 1018 1021 998 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 1163 1164 1143 1144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1173 1174 1149 1150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1177 1178 1153 1154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1253 1254 1225 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1257 1258 1229 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1271 1272 1239 1240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1275 1276 1243 1244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1375 1381 1343 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 1414 1415 1378 1379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1418 1419 1382 1383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1552 1553 1512 1513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1556 1557 1516 1517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1577 1578 1533 1534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1581 1582 1537 1538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1772 1773 1724 1725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1776 1777 1728 1729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1799 1800 1747 1748 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1803 1804 1751 1752 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2082 2088 2022 2028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 2108 2111 2048 2051 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2120 2121 2056 2057 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2124 2125 2060 2061 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2453 2454 2373 2374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2457 2458 2377 2378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2592 2593 2508 2509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2596 2597 2512 2513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2625 2631 2541 2547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 2743 2744 2651 2652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2747 2748 2655 2656 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2821 2827 2729 2735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
###xml 1128 1133 <span type="species:ncbi:10090">mouse</span>
###xml 1449 1453 <span type="species:ncbi:10090">mice</span>
Given that DCs are the main producers of IL-12 and that the neonatal environment is composed of lower numbers of DCs relative to other APCs (11), it is possible that the inability of the neonatal environment to provide significant IL-12 is related to the minimal number of Ag-presenting DCs available at day 1 after birth. In fact, when newborn mice were enriched with adult IL-12+/+ splenic DCs, up-regulation of IL-13Ralpha1 on primary Th1 cells was minimal, apoptosis was significantly reduced, and secondary Th1 IFN-gamma responses were restored (Fig. 5). IL-12-/- DCs could not inhibit IL-13Ralpha1 up-regulation or restore Th1 IFN-gamma responses. These observations, together with the day 6-acquired neonatal transition to secondary Th1 responses, suggest that developmental accumulation of DCs could be responsible for the bias of neonatal immunity toward Th2. Given that distinct subsets of DCs can perform different functions (24-27), delayed developmental accumulation of a specific subset of CD8alpha+/-CD4+/- DCs over time could orchestrate the Th2 bias of neonatal immunity. Analysis of DC ontogeny in the neonate mouse indicated that although CD11c+ CD8alpha-CD4- DCs were present at a significant number on the day of birth, the CD8alpha+CD4- and CD8alpha-CD4+ subsets began to accumulate in the spleen by day 4 and reached a significant percentage by day 6 (Fig. 6). A small population of CD8alpha+CD4+ DCs that is present in adult mice was not detected by day 10 after birth. Thus, these observations suggested that it is the CD8alpha+CD4- and/or the CD8alpha-CD4+ subset that might be responsible for the acquired ability of the neonate to develop secondary Th1 responses when exposure to Ag is performed on day 6 after birth. In fact, when the CD8alpha+CD4-, but not the CD8alpha-CD4+, subset was transferred to newborns on the day of birth during exposure to Ag, the primary Th1 cells displayed significantly reduced IL-13Ralpha1 expression, resisted apoptosis, and developed secondary IFN-gamma responses when the animals were rechallenged with OVA as adults (Fig. 7). Transfer of IL-12-/- CD8alpha+CD4- DCs was not able to overturn IL-13Ralpha1 up-regulation or restore IFN-gamma secondary Th1 responses, indicating that the subset presents Ag and produces the IL-12 needed to counter IL-13Ralpha1 up-regulation. Moreover, investigation of the frequency of the DC subsets indicated that a minimal number of the presenting CD8alpha+CD4- DC subset is present in the spleen on the day of birth. At best, these cells could produce IL-12 at a limited rate, like the CD8alpha-CD4- double-negative DC subset (Fig. 8), but this would be insufficient to counter IL-13Ralpha1 up-regulation. By day 6, the frequency of the CD8alpha+CD4- DC subset increased because of significant accumulation of this subset (Fig. 8). In addition, most of the cells produced IL-12, leading to inhibition of IL-13Ralpha1 up-regulation, diminished apoptosis of primary Th1 cells, and development of secondary Th1 responses.
###end p 34
###begin p 35
###xml 278 279 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 282 283 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 446 448 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 450 452 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 609 610 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 712 714 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 716 718 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 930 931 902 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 934 935 906 907 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1039 1040 1007 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1043 1044 1011 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1429 1431 1393 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1407 1414 <span type="species:ncbi:9606">infants</span>
###xml 1419 1427 <span type="species:ncbi:9606">children</span>
Collectively, these observations indicate that delayed developmental maturation of a subset of DCs operates the Th2 bias of neonatal immunity. In particular, our data suggest that minimal production of IL-12 in early neonatal life because of delayed accumulation of the CD8alpha+CD4- DC subset leads to up-regulation of IL-13Ralpha1 on primary Th1 cells. This chain associates with IL-4Ralpha and forms an IL-4Ralpha/IL-13Ralpha1 heteroreceptor (13, 14). IL-4 from the Th2 cells used this receptor to drive apoptosis of Th1 cells, leading to a lack of secondary Th1 immunity, and hence the bias to Th2 cells (9). These observations agree with previous papers showing a delayed developmental accumulation of DCs (28, 29). What this study adds is that a specific subset is responsible for Ag presentation and IL-12 production, and it ties the regulation of IL-13Ralpha1 to such IL-12 and the developmental maturation of the CD8alpha+CD4- DC subset during the neonatal period. Also, we demonstrate that sufficient accumulation of the CD8alpha+CD4- DC subset by day 6 after birth represents a turning point to down-regulate IL-13Ralpha1 and sustain the transition for Th1 responses. These previously unrecognized findings highlight the mechanism underlying the bias of neonatal immunity toward Th2 cells and provide useful information for the development of pediatric vaccines and reagents against allergies in infants and children (30).
###end p 35
###begin title 36
MATERIALS AND METHODS
###end title 36
###begin title 37
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 37
###begin p 38
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 223 226 223 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 245 253 245 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-12p35</italic>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 383 390 <span type="species:ncbi:9986">rabbits</span>
BALB/c (H-2d) mice were purchased from Harlan Sprague Dawley and were used as hosts for the adoptive transfer of T cells. DO11.10/scid Tg mice expressing a TCR specific for OVA peptide (10) were used as T cell donors. IL-12-/- mice in which the IL-12p35 gene was knocked out (20) were obtained from the Jackson Laboratory and were used as a source for DC transfer. New Zealand white rabbits were purchased from Myrtle's Rabbitry. All animals were maintained in the animal facility for the duration of the experiments. Experimental procedures performed on these animals were conducted according to the guidelines of the University of Missouri Columbia Animal Care and Use Committee.
###end p 38
###begin title 39
Ag's
###end title 39
###begin p 40
###xml 103 104 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
OVA peptide (SQAVHAAHAEINEAGR) encompasses aa residues 323-339 of OVA and is immunogenic in BALB/c (H-2d) mice. Ig-W, a BALB/c IgG2b Ig molecule generated by transfection of the 91A3 antiarsonate antibody heavy and light chains into the non-Ig-secreting myeloma B cell line SP2/0, was previously described (4). Ig-OVA, expressing OVA peptide within the heavy chain variable region of Ig-W, was also previously described (11). ODN1826 or CpG oligonucleotide was purchased from InvivoGen.
###end p 40
###begin title 41
###xml 14 20 <span type="species:ncbi:9986">rabbit</span>
Generation of rabbit anti-IL-13Ralpha1 antibodies
###end title 41
###begin title 42
Expression and purification of IL-13Ralpha1 protein.
###end title 42
###begin p 43
###xml 32 34 28 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 618 620 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
The plasmid pQE30-IL-13Ralpha1 (31), a gift from A. Gessner (Institut fur Klinische Mikrobiologie, Immunologie und Hygiene, Erlangen, Germany), was digested with SphI and XhoI to liberate a cDNA that encodes the extracellular domain of IL-13Ralpha1 (aa 27-339) with an N-terminal His tag. This fragment was ligated into pFastBac plasmid (Invitrogen) to generate pFastBac-IL-13Ralpha1, which was then used to generate baculovirus and to express rmIL-13Ralpha1 in Sf9 cells, according to the manufacturer's instructions. IL-13Ralpha1 protein was purified using Ni-NTA agarose beads from QIAGEN, as previously described (32).
###end p 43
###begin title 44
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
Rabbit immunization with IL-13Ralpha1 protein.
###end title 44
###begin p 45
###xml 104 106 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 20 26 <span type="species:ncbi:9986">rabbit</span>
###xml 70 73 <span type="species:ncbi:31658">CFA</span>
A New Zealand white rabbit was immunized with 50 mug rIL-13Ralpha1 in CFA/PBS, as previously described (33). A subsequent immunization with 50 mug rIL-13Ralpha1 in IFA/PBS was given monthly for 3 mo.
###end p 45
###begin title 46
Adoptive T cell transfer
###end title 46
###begin p 47
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 715 716 715 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 572 576 <span type="species:ncbi:10090">mice</span>
###xml 814 818 <span type="species:ncbi:10090">mice</span>
Splenic cells from 1-day-old DO11.10/scid mice containing the equivalent of 30 x 103 DO11.10 T cells were transferred into 1-day-old BALB/c mice by i.v. injection through the facial vein using a 30-gauge needle. To obtain four experimental newborn BALB/c hosts, 12 DO11.10/scid neonatal mice were used. For the transfer of adult T cells into newborn mice, DO11.10 T cells were purified from the spleens of adult DO11.10/scid mice with anti-CD4 antibody-coupled magnetic beads (Miltenyi Biotec) before injection into the host. In this case, two to three adult DO11.10/scid mice are needed to generate four neonatal BALB/c hosts. When the analysis requires separation of Th1 from Th2 cells, the transfer used 300 x 103 purified rather unseparated neonatal DO11.10/scid T cells. In this case, 60 newborn DO11.10/scid mice are needed to generate four BALB/c hosts. This 10-fold increase in T cell transfer was required for the isolation of sufficient numbers of T cells for RNA extraction and spot blot and real-time PCR analysis.
###end p 47
###begin title 48
Detection of apoptosis by staining with Annexin V
###end title 48
###begin p 49
###xml 310 315 <span type="species:ncbi:10090">mouse</span>
###xml 616 621 <span type="species:ncbi:10090">mouse</span>
For cell-surface staining, the splenic cells from BALB/c hosts that received neonatal DO11.10/scid T cells and Ig-OVA were incubated for 20 min at 4degreesC with 5 mug/ml 2.4G2 mAb to block FcgammaRs on the cell surface before staining. The cells were then stained with the anti-TCR OVA clonotypic mAb KJ1-26 (mouse IgG2a) and FITC-Annexin V (BD Biosciences). Cytokine secretion was blocked by the addition of 10 mug/ml Brefeldin A (BFA; Epicentre), and the cells were fixed with 2% formaldehyde, permeabilized with 2% saponin (Sigma-Aldrich) in PBS buffer for 10 min at room temperature, and incubated with PE-anti-mouse IFN-gamma. Isotype-matched controls were included in all experiments. All data were collected using a flow cytometer (FACScan; Becton Dickinson) and were analyzed with CellQuest software (Becton Dickinson) and Flowjo software (Tree Star, Inc.).
###end p 49
###begin title 50
Separation of Th1 cells
###end title 50
###begin p 51
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 546 547 546 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 551 552 551 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 905 907 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 1397 1398 1373 1374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 1446 1447 1422 1423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
###xml 632 636 <span type="species:ncbi:10090">mice</span>
###xml 1024 1029 <span type="species:ncbi:10090">mouse</span>
The separation of neonatal Th1 from Th2 cells requires an increased frequency of primary T lymphocytes. To overcome this technical difficulty, the transfer was performed with purified neonatal DO11.10/scid T lymphocytes instead of total splenic cells, and the number of transferred cells was increased from 30 to 300 x 103 cells per newborn BALB/c host. Consequently, each T cell subset isolation experiment used four neonatal BALB/c hosts that required cells from 60 newborn DO11.10/scid mice. Accordingly, each BALB/c newborn was given 300 x 103 CD4+-DO11.10 T cells purified from the spleens of neonatal (1-day-old) DO11.10/scid mice, and the hosts were injected i.p. with a saline solution containing 100 mug Ig-OVA. 2 wk later, the splenic T cells were stimulated for 10 h with 10 muM OVA peptide, and Th1 cells were separated on the basis of cytokine secretion (IFN-gamma), as previously described (34), using separation kits (Miltenyi Biotec). In brief, after peptide stimulation the spleen cells were incubated with mouse IFN-gamma catch reagent for 45 min, and the cell surface-captured cytokine was used to attach PE-conjugated anticytokine mAb by incubation with PE-anti-IFN-gamma for 10 min on ice. Anti-PE-coupled microbeads were added, and the cells were incubated for 15 min at 4degreesC. Subsequently, IFN-gamma-producing cells were separated by MACS (Miltenyi Biotec). Usually, 108 splenic cells are used to obtain from 0.5 to 106 Th1 cells.
###end p 51
###begin title 52
Detection of a subset of DCs
###end title 52
###begin p 53
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
For cell-surface staining, the splenic cells (106 cells/ml) from different ages (1, 2, 4, 6, 8, and 10 d old) of BALB/c neonates were incubated for 20 min at 4degreesC with 5 mug/ml 2.4G2 mAb to block FcgammaRs on the cell surface and were stained with anti-CD11c for 30 min. Subsequently, the cells were stained with FITC-labeled anti-CD8alpha and PE-labeled anti-CD4 (BD Biosciences), and fixed with 2% formaldehyde.
###end p 53
###begin title 54
Isolation of DCs
###end title 54
###begin p 55
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 445 446 433 434 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
For the isolation of bulk splenic DCs, spleens from adult BALB/c or IL-12-/- mice were collected and purified according to the standard collagenase/differential adherence method (35). In brief, the spleen was disrupted in a collagenase solution, and isolated DCs were floated on a dense BSA gradient. Subsequently, the cells were allowed to adhere to Petri dishes for 90 min at 37degreesC, washed, and incubated overnight at 37degreesC and 7% CO2. The next day, floating DCs were harvested and used for transfer experiments. In some experiments, adult DCs were purified using anti-CD11c mAb-coupled microbeads (Miltenyi Biotec). Isolation of splenic DCs from neonates used 45 newborns for each time point and was performed using anti-CD11c mAb coupled to microbeads, as described.
###end p 55
###begin p 56
###xml 153 154 145 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 167 168 155 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 217 218 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 221 222 205 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 235 236 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 239 240 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 264 265 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
For the isolation of DC subsets, the bulk DCs were incubated with anti-CD8alpha mAb-coupled microbeads (Miltenyi Biotec) and were separated into CD8alpha+ and CD8alpha- populations by MACS. For preparation of CD8alpha+CD4- and CD8alpha-CD4+DC subsets, the CD8alpha- fraction was labeled with anti-CD4 mAb-coupled microbeads and separated by MACS. Each fraction was assessed for purity, and no population was used if contamination was >5%.
###end p 56
###begin title 57
Treatment with rIL-12 and anti-IL-12 antibodies
###end title 57
###begin p 58
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 372 375 <span type="species:ncbi:10116">Rat</span>
In vivo injection of rIL-12 (PeproTech) used 50 ng of cytokine in PBS injected i.p., together with Ig-OVA, within 24 h after T cell transfer. The mice were given two more injections (50 ng in PBS) 48 and 72 h later. Control groups were injected with PBS without cytokine. For neutralization of IL-12, we used C17.8 anti-IL-12 mAb (BD Biosciences), which was injected i.p. Rat IgG was used as a control.
###end p 58
###begin title 59
Cytokine ELISA and ELISPOT
###end title 59
###begin title 60
Measurement of cytokines by ELISA.
###end title 60
###begin p 61
Splenic cells containing both T cells and APCs were incubated with Ag in 96-well round-bottom plates for 24 h. IFN-gamma production was measured by ELISA using anticytokine antibodies according to BD Bioscience's instructions.
###end p 61
###begin title 62
Measurement of IFN-gamma by ELISPOT.
###end title 62
###begin p 63
###xml 73 74 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 76 77 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 262 263 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 234 238 <span type="species:ncbi:9913">calf</span>
Detection of IFN-gamma by ELISPOT was performed as previously described (4, 9). In brief, HA-Multiscreen plates (Millipore) were coated with capture antibody, and free sites were saturated with DMEM culture media containing 10% fetal calf serum. Subsequently, 106 splenic cells were added and the culture was stimulated with OVA peptide with or without blocking antibody. 1 mug/ml of biotinylated anti-IFN-gamma antibody was added, and bound antibody was revealed with avidin-peroxidase. Spots were counted using Immunospot software (Cellular Technology Ltd.).
###end p 63
###begin title 64
###xml 27 39 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-13R&#945;1</italic>
Spot blot for detection of IL-13Ralpha1 expression
###end title 64
###begin p 65
###xml 217 229 217 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-13R&#945;1</italic>
###xml 296 308 292 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-13R&#945;1</italic>
###xml 488 493 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 869 870 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 899 902 872 875 <sc xmlns:xlink="http://www.w3.org/1999/xlink">zol</sc>
###xml 990 992 958 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Because of the small number of isolated Th1 cells, RNA purification yields small amounts insufficient to perform Northern blot analysis. We developed a spot-blot technology to overcome these limitations and performed IL-13Ralpha1 analysis by both spot blot and real-time PCR. Accordingly, a 1-kb IL-13Ralpha1 DNA fragment was digested from pCEP4IL-13Ralpha1 plasmid with BamH1 and purified by electroelution from a 1% agarose gel. 1 mul Tris buffer containing 5 ng IL-13Ralpha1, pUC19 or GAPDH DNA was deposited within marked circular spots on a nylon transfer membrane (Magnacharge; Osmonics). Duplicate spots were made for each sample. The membrane was dried for 30 min at 60degreesC, and the DNA was denatured in 0.5 N NaOH and neutralized with 0.5 M Tris buffer. The membrane was then used for detection of IL-13Ralpha1 mRNA. Total RNA was extracted from 0.5-1 x 106 purified Th1 cells using TRIzol reagent (Life Technologies). 5 mug RNA was used in an RT reaction together with alpha-[32P]dCTP (GE Healthcare) to generate labeled cDNA probes by using the Ampolabeling-LRP kit (SuperArray Inc.). The specific primers for the amplification of target genes were purchased from SuperArray Inc. Subsequently, the labeled cDNA probes were hybridized to the membrane in a 0.75-ml hybridization buffer for 24 h at 60degreesC. The intensity of radioactive spots was analyzed on a Molecular Imager FX (Bio-Rad Laboratories) using Quantity One software. Results were expressed as arbitrary units estimated as follows: (mean spot density of sample - mean spot density of background)/(mean spot density of GAPDH - mean spot density of background). The background represents the mean radioactive intensity obtained from pUC19 DNA spots included in the membrane.
###end p 65
###begin title 66
Real-time PCR
###end title 66
###begin p 67
###xml 691 692 670 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
RT and DNA amplification were performed according to a one-step protocol using 200 ng of total RNA and an Absolute MAX QRT-PCR SYBR Mix (ABgene), according to the manufacturer's instructions. Expression of IL-13Ralpha1 chain mRNA was assessed in neonatal Th1 cells. beta-actin was included to serve as a normalizer. The oligonucleotides used as specific primers were as follows: sense, (IL-13Ralpha1) 5'-GCACAGAGTATAGGTAAGGAGCAA-3' and (beta-actin) 5'-AGAGGGAAATCGTGCGTGAC-3'; and antisense, (IL-13Ralpha1) 5'-ACAAAGACTGGAATGGTGAGTAAC-3' and (beta-actin) 5'-CAATAGTGATGACCTGGCCGT-3'. Real-time PCR was performed on a Smart Cycler (Cepheid), and the results were analyzed by the comparative CT method described by the Smart Cycler software.
###end p 67
###begin p 68
This work was supported by National Institute of Allergy and Infectious Diseases grants RO1AI48541 and R21AI062796 (to H. Zaghouani) and by the J. Lavenia Edwards Chair endowment (to H. Zaghouani). J.S. Ellis and C.M. Hoeman were supported by a training grant from the National Institute of General Medical Sciences. J.C. Hardaway and D.M. Tartar were supported by Life Sciences fellowships from the University of Missouri.
###end p 68
###begin p 69
The authors have no conflicting financial interests.
###end p 69

